Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/127053| Author(s): | Bettencourt-Silva, R Queirós, J Pereira, J Carvalho, D |
| Title: | Giant prolactinoma, germline BRCA1 mutation, and depression: A case report 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis |
| Publisher: | BMC |
| Issue Date: | 2018 |
| Abstract: | Background: Giant prolactinomas are very rare pituitary tumors that may exhibit an aggressive behavior and present with a life-threatening condition. Case presentation: A 25-year-old white woman was admitted to our hospital with a headache, psychomotor retardation, reduced vision, and loss of autonomy in daily activities. Her past medical history was significant for having oligomenorrhea and a depressive syndrome since her mother's death. She also had a breast cancer gene 1 (BRCA1) mutation and a family history of breast cancer. She had marked hyperprolactinemia (7615 ng/dL), central hypocortisolism, growth hormone deficiency, and a giant pituitary tumor (52 × 30 × 33 mm) which was shown in magnetic resonance imaging with obstructive hydrocephalus, requiring emergency surgery. Treatment with cabergoline led to a 99.8% reduction in serum prolactin levels and significant tumor shrinkage. Her depressive symptoms progressively improved and psychiatric drugs were withdrawn after 3 months of cabergoline treatment. Currently, she is being followed in Endocrinology, Neurosurgery, and Neurophthalmology out-patient clinics and in a breast cancer unit. Careful monitoring, support, and follow-up will be essential throughout this patient's life. Conclusions: This case is a rare presentation of a giant prolactinoma in a young woman, who presented a life-threatening event. She also had an unexpected association between diseases or symptoms that may have contributed to the delay in diagnosis. Given the concomitant presence of a giant prolactinoma, a BRCA1 mutation, and depressive symptoms, a possible association was hypothesized. The breast cancer risk in a BRCA1 mutation carrier and the possible interference of hyperprolactinemia and life events were also discussed. However this hypothesis requires further investigation. |
| DOI: | 10.1186/s13256-018-1890-x |
| URI: | https://hdl.handle.net/10216/127053 |
| Source: | Journal of Medical Case Reports, vol.12(1):360 |
| Document Type: | Artigo em Revista Científica Internacional |
| Rights: | openAccess |
| License: | https://creativecommons.org/licenses/by/4.0/ |
| Appears in Collections: | I3S - Artigo em Revista Científica Internacional |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 10.1186-s13256-018-1890-x.pdf | 3.84 MB | Adobe PDF | ![]() View/Open |
This item is licensed under a Creative Commons License
